Prenatal dexamethasone treatment of congenital adrenal hyperplasia: are we any closer to considering it safe? (2023)
- Authors:
- USP affiliated authors: CASTRO, MARGARET DE - FMRP ; MARTINS, CLARISSA SILVA - FMRP ; ANTONINI, SONIR ROBERTO RAUBER - FMRP
- Unidade: FMRP
- DOI: 10.1210/clinem/dgac524
- Subjects: HIPERPLASIAS; DIAGNÓSTICO PRÉ-NATAL; DOENÇAS GENÉTICAS; HORMÔNIOS GLICOCORTICOIDES; CÉREBRO
- Keywords: Congenital adrenal hyperplasia; Prenatal dexamethasone treatment; Brain function
- Language: Inglês
- Imprenta:
- Source:
- Título: The Journal of Clinical Endocrinology & Metabolism
- ISSN: 0021-972X
- Volume/Número/Paginação/Ano: v. 108, n. 1, p. e9-e10, 2023
- Status:
- Artigo possui acesso gratuito no site do editor (Bronze Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
CASTRO, Margaret de e MARTINS, Clarissa Silva e ANTONINI, Sonir Roberto Rauber. Prenatal dexamethasone treatment of congenital adrenal hyperplasia: are we any closer to considering it safe?. The Journal of Clinical Endocrinology & Metabolism, v. 108, n. 1, p. e9-e10, 2023Tradução . . Disponível em: https://doi.org/10.1210/clinem/dgac524. Acesso em: 31 mar. 2026. -
APA
Castro, M. de, Martins, C. S., & Antonini, S. R. R. (2023). Prenatal dexamethasone treatment of congenital adrenal hyperplasia: are we any closer to considering it safe? The Journal of Clinical Endocrinology & Metabolism, 108( 1), e9-e10. doi:10.1210/clinem/dgac524 -
NLM
Castro M de, Martins CS, Antonini SRR. Prenatal dexamethasone treatment of congenital adrenal hyperplasia: are we any closer to considering it safe? [Internet]. The Journal of Clinical Endocrinology & Metabolism. 2023 ; 108( 1): e9-e10.[citado 2026 mar. 31 ] Available from: https://doi.org/10.1210/clinem/dgac524 -
Vancouver
Castro M de, Martins CS, Antonini SRR. Prenatal dexamethasone treatment of congenital adrenal hyperplasia: are we any closer to considering it safe? [Internet]. The Journal of Clinical Endocrinology & Metabolism. 2023 ; 108( 1): e9-e10.[citado 2026 mar. 31 ] Available from: https://doi.org/10.1210/clinem/dgac524 - Generalized and tissue specific glucocorticoid resistance
- Integrating molecular and metabolomic markers in T1D enables precocious interventions: are we getting there?
- Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis
- miR-449 does not regulate Wnt pathway genes in adrenocortical tumor cell line
- Letter to the Editor. [Carta]: comments on "LGR5 activates noncanonical Wnt signaling and inhibits aldosterone production in the human adrenal" by Shaikh L. H., et al
- Papel dos reguladores da tradução do gene CDKN1B, codificador de P27, na tumorigênese hipofisária
- Commom polymorphisms in GHRd3, IGFBP3 and IGF1 genes do not explain GH-IGF-I dissociation in treated acromegalic patients
- Time course of central precocious puberty development caused by an MKRN3 gene mutation: a prismatic care
- Mechanisms in endocrinology: a sense of time of the glucocorticoid circadian clock: from the ontogeny to the diagnosis of Cushing’s syndrome
- Anti-proliferative, pro-apoptotic and anti-steroidogenic effcts of TCF/7beta-catenin complex inhibition in adrenocortical tumor cells
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
